title: Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"?
abstract: The year 2014 was a turning point for the field of renal denervation (RDN) and its potential use to treat resistant hypertension. Tremendous enthusiasm shifted to sober reflection on the efficacy of a technology once touted as the cure to resistant hypertension. The following review highlights 2 major questions: First, does catheter-based RDN lower blood pressure and, second, will RDN using catheter-directed therapy for the treatment of resistant hypertension ever become more than an investigational technology.
authors.affiliation: Section of Endocrinology, Diabetes and Metabolism, ASH Comprehensive Hypertension Center, Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.|Section of Cardiology, Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.
authors.forename: Luke J
authors.initials: LJ
authors.lastname: Laffin
authors.affiliation: Section of Endocrinology, Diabetes and Metabolism, ASH Comprehensive Hypertension Center, Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.
authors.forename: George L
authors.initials: GL
authors.lastname: Bakris
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D017115:Catheter Ablation / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D007668:Kidney / Q000098:blood supply*; D012077:Renal Artery / Q000294:innervation*; D012307:Risk Factors; D013562:Sympathectomy / Q000009:adverse effects / Q000379:methods*; D013564:Sympathetic Nervous System / Q000503:physiopathology / Q000601:surgery*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents
keywords: blood pressure; denervation; hypertension; treatment